Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.THE first large-scale clinical trials of a vaccine designed to prevent infection with the Aids virus should begin next year, a leading scientist said yesterday.
Two candidate vaccines have been identified, both of which trigger a strong immune system response over several months to more than one strain of the virus, with minimal side effects in healthy volunteers. The level of antibodies produced is similar to that seen in people infected with the live HIV virus.
The vaccines have progressed to phase two trials - the only two vaccines to have done so - in healthy high-risk volunteers. Plans to recruit thousands more healthy volunteers in the US for the third and final phase of trials are under way for 1994 and 1995.
Dr Dani Bolognesi, director of the Central Immunology Laboratory at Duke University, North Carolina, told the international Aids conference in Berlin: 'HIV vaccine development can be considered at a crossroads, and is in a position to turn a corner'. Another 20 candidate vaccines are in preliminary trials worldwide.
Reports of promising vaccines are a feature of every Aids conference, but Dr Bolognesi gave the most positive report to date.
The two vaccines, known as rgp 120MN and rgp 120 SF-2, trick the body into thinking HIV has infected it. To imitate HIV, scientists used genetic engineering techniques to recreate the outer coat of the virus. The immune system should respond by producing cells which target and destroy HIV. Refinements in the genetic engineering technique used to produce parts of the viral coat mean they now mimic the live virus much more closely than early attempts.
Three doses of rgp 120MN vaccine given over six months stimulated antibodies to three strains of the virus. Three doses of the second vaccine also produced high levels of antibodies to three different strains.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments